Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Reschke

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|June 9, 2019
[Pitfall cryothermic dermatitis artefacta]Mirjana Ziemer, Manfred Kunz, Monica Schüürmann, et al.
Wounds : a Compendium of Clinical Research and Practice|April 19, 2021
Erosive Pustular Dermatosis of the Scalp: Clinicopathological Correlation Leading to a Definition of Diagnostic CriteriaRobin Reschke, Sonja Grunewald, Uwe Paasch, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanomaRobin Reschke, Jovian Yu, Blake Flood, et al.
Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.
Cancer Immunology Research|August 17, 2022
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 CytokinesRobin Reschke, Jason W Shapiro, Jovian Yu, et al.
Cancers|August 12, 2023
Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary GlandsFelix Johnson, Benedikt Hofauer, Markus Wirth, et al.
International Journal of Molecular Sciences|August 7, 2021
Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor TherapyRobin Reschke, Philipp Gussek, Andreas Boldt, et al.
Diagnostics (Basel, Switzerland)|April 13, 2024
Predictive Value of Dual-Energy CT-Derived Metrics for the Use of Bone Substitutes in Distal Radius Fracture SurgeryPhilipp Reschke, Vitali Koch, Scherwin Mahmoudi, et al.
Journal for Immunotherapy of Cancer|January 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanomaRobin Reschke, Petra Budde, Hans-Dieter Zucht, et al.
Journal for Immunotherapy of Cancer|May 31, 2023
Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitorsJulia-Christina Stadler, Laura Keller, Christian Mess, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete|June 9, 2019
[Pitfall cryothermic dermatitis artefacta]Mirjana Ziemer, Manfred Kunz, Monica Schüürmann, et al.
Wounds : a Compendium of Clinical Research and Practice|April 19, 2021
Erosive Pustular Dermatosis of the Scalp: Clinicopathological Correlation Leading to a Definition of Diagnostic CriteriaRobin Reschke, Sonja Grunewald, Uwe Paasch, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanomaRobin Reschke, Jovian Yu, Blake Flood, et al.
Trends in Immunology|December 28, 2024
Targeting molecular pathways to control immune checkpoint inhibitor toxicitiesRobin Reschke, Ryan J Sullivan, Evan J Lipson, et al.
Cancer Immunology Research|August 17, 2022
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 CytokinesRobin Reschke, Jason W Shapiro, Jovian Yu, et al.
Cancers|August 12, 2023
Novel Discovery of the Somatostatin Receptor (SSTR2) in Pleomorphic Adenomas via Immunohistochemical Analysis of Tumors of the Salivary GlandsFelix Johnson, Benedikt Hofauer, Markus Wirth, et al.
International Journal of Molecular Sciences|August 7, 2021
Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor TherapyRobin Reschke, Philipp Gussek, Andreas Boldt, et al.
Diagnostics (Basel, Switzerland)|April 13, 2024
Predictive Value of Dual-Energy CT-Derived Metrics for the Use of Bone Substitutes in Distal Radius Fracture SurgeryPhilipp Reschke, Vitali Koch, Scherwin Mahmoudi, et al.
Journal for Immunotherapy of Cancer|January 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanomaRobin Reschke, Petra Budde, Hans-Dieter Zucht, et al.
Journal for Immunotherapy of Cancer|May 31, 2023
Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitorsJulia-Christina Stadler, Laura Keller, Christian Mess, et al.
Pageof 5